human coagulation factor viii
PolandDrugs containing this active substance
-
The medicinal product is used for the treatment and prophylaxis of bleeding in patients with congenital haemophilia A, for the treatment of bleeding in patients with acquired factor VIII deficiency, and in patients with haemophilia who have developed antibodies against factor VIII (inhibitors).
Form: powder and solvent for solution for injection and infusion
Active substance Dosage human coagulation factor viii 500 j.m. ATC: B02BD02
Manufacturer: Kedrion S.p.A.
-
The medicinal product is used for the treatment and prophylaxis of bleeding in individuals with congenital haemophilia A, for the treatment of bleeding in individuals with acquired factor VIII deficiency, and for the treatment of haemophiliac patients who have developed antibodies against factor VIII (inhibitors).
Form: powder and solvent for solution for injection and infusion
Active substance Dosage human coagulation factor viii 1000 j.m. ATC: B02BD02
Manufacturer: Kedrion S.p.A.
-
The medicinal product is used for the prophylaxis and treatment of bleeding caused by a deficiency of von Willebrand factor (von Willebrand disease) or a deficiency of factor VIII (haemophilia A). It may also be used in the therapy of acquired factor VIII deficiency and in patients with antibodies against it.
Form: solution for injection or infusion, powder and solvent for preparation of
Active substance Dosage human coagulation factor viii 1000 j.m. von willebrand factor human 2400 j.m. ATC: B02BD06
Manufacturer: CSL Behring GmbH
-
The medicinal product is used for the prophylaxis and treatment of bleeding in individuals with von Willebrand disease and in haemophilia A (factor VIII deficiency). It may also be used in the therapy of acquired factor VIII deficiency and in patients possessing antibodies against this factor.
Form: solution for injection or infusion, powder and solvent for preparation of
Active substance Dosage human coagulation factor viii 250 j.m. von willebrand factor human 600 j.m. ATC: B02BD06
Manufacturer: CSL Behring GmbH
-
The medicinal product is used for the prophylaxis and treatment of bleeding caused by a deficiency of von Willebrand factor (von Willebrand disease) or a deficiency of factor VIII (haemophilia A). It may also be used in the treatment of acquired factor VIII deficiency and in patients with antibodies against it.
Form: solution for injection or infusion, powder and solvent for preparation of
Active substance Dosage human coagulation factor viii 500 j.m. von willebrand factor human 1200 j.m. ATC: B02BD06
Manufacturer: CSL Behring GmbH
-
The medicinal product is used for the treatment and prevention of bleeding in congenital (haemophilia A) or acquired factor VIII deficiency. It may also be used for the treatment of bleeding in patients with von Willebrand disease if other methods are ineffective or contraindicated.
Form: solution for injection, powder and solvent for preparation of
Active substance Dosage human coagulation factor viii 100 j.m./ml von willebrand factor human 75 j.m./ml ATC: B02BD02
Manufacturer: Takeda Manufacturing Austria AG
-
The medicinal product is used for the treatment and prevention of bleeding in congenital (haemophilia A) or acquired factor VIII deficiency. It is also used for the treatment of bleeding in patients with von Willebrand disease if other methods are ineffective or contraindicated.
Form: solution for injection, powder and solvent for preparation of
Active substance Dosage human coagulation factor viii 50 j.m./ml von willebrand factor human 38 j.m./ml ATC: B02BD02
Manufacturer: Takeda Manufacturing Austria AG
-
The medicinal product is used for the treatment and prevention of bleeding in congenital (haemophilia A) or acquired factor VIII deficiency. It may also be used for the treatment of bleeding in patients with von Willebrand disease if other treatment methods are ineffective or contraindicated.
Form: solution for injection, powder and solvent for preparation of
Active substance Dosage human coagulation factor viii 100 j.m./ml von willebrand factor human 75 j.m./ml ATC: B02BD02
Manufacturer: Takeda Manufacturing Austria AG
-
The medicinal product is used for the treatment and prevention of bleeding in patients with haemophilia A, which results from a deficiency of coagulation factor VIII in the blood.
Form: powder and solvent for solution for injection and infusion
Active substance Dosage human coagulation factor viii 50 j.m./1 ml ATC: B02BD02
Manufacturer: Octapharma AB Octapharma Pharmazeutika Produktionsgesellschaft GmbH (OPG) Octapharma S.A.S.
-
The medicine is used for the treatment and prevention of bleeding in people with haemophilia A, which results from a congenital deficiency of coagulation factor VIII in the blood.
Form: solution for injection, powder and solvent for preparation of
Active substance Dosage human coagulation factor viii 100 j.m./1 ml ATC: B02BD02
Manufacturer: Octapharma AB Octapharma Pharmazeutika Produktionsgesellschaft GmbH (OPG) Octapharma S.A.S.
-
The medicine is used for the treatment and prevention of bleeding in people with hemophilia A, which results from a congenital deficiency of coagulation factor VIII in the blood.
Form: solution for injection, powder and solvent for preparation of
Active substance Dosage human coagulation factor viii 100 j.m./ml ATC: B02BD02
Manufacturer: Octapharma AB
-
It is a medicinal product containing human coagulation factor VIII, which is supplied as a powder for solution for injection.
Form: solution for injection, powder and solvent for preparation of
Active substance Dosage human coagulation factor viii 200 j.m./ml ATC: B02BD02
Manufacturer: Octapharma AB
-
The medicine is used for the treatment and prevention of bleeding in patients with hemophilia A, which results from a deficiency of coagulation factor VIII in the blood.
Form: solution for injection, powder and solvent for preparation of
Active substance Dosage human coagulation factor viii 100 j.m./ml ATC: B02BD02
Manufacturer: Octapharma AB Octapharma Pharmaceuticals Production GmbH Octapharma SAS
-
Pharmavate is used for the treatment and prevention of bleeding in patients with hemophilia A, which results from a deficiency of coagulation factor VIII in the blood.
Form: solution for injection, powder and solvent for preparation of
Active substance Dosage human coagulation factor viii 50 j.m./ml ATC: B02BD02
Manufacturer: Octapharma AB Octapharma Pharmaceuticals Production GmbH Octapharma SAS
-
Wilate is used for the treatment and prevention of bleeding in individuals suffering from von Willebrand disease and in patients with haemophilia A.
Form: solution for injection, powder and solvent for preparation of
Active substance Dosage human coagulation factor viii 1000 j.m. von willebrand factor human 1000 j.m. ATC: B02BD06
Manufacturer: Octapharma GmbH
-
Wilate is used for the treatment and prevention of bleeding in individuals suffering from von Willebrand disease and in patients with haemophilia A.
Form: solution for injection, powder and solvent for preparation of
Active substance Dosage human coagulation factor viii 500 j.m. von willebrand factor human 500 j.m. ATC: B02BD06
Manufacturer: Octapharma GmbH